First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline –– Announced FDA Approval of VEPPANU™ ...
A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits ...
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Veppanu leverages PROTAC-mediated ubiquitin–proteasome degradation to eliminate mutant estrogen receptor, aiming to bypass ESR1-driven endocrine resistance rather than merely inhibiting receptor ...
The FDA has approved Pfizer and Arvinas’ Veppanu, the first proteolysis-targeting chimera (PROTAC) therapy, for advanced ER-positive, HER2-negative breast cancer with ESR1 mutations after prior ...
Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved ...
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...
Heat shock protein 90 (Hsp90) consists of four isoforms. Among them, the Hsp90α is overexpressed in advanced tumors and involved in tissue repair, tumor migration and metastasis as well. Researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results